What SEC filings does BridgeBio Pharma, Inc. submit to the SEC?

BridgeBio Pharma, Inc. (BBIO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BBIO?

A Form 4 for BBIO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from BridgeBio Pharma, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BBIO?

The 10-K is BridgeBio Pharma, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BBIO SEC filings directly on EDGAR?

You can view all historical BridgeBio Pharma, Inc. filings on the SEC EDGAR company page for BBIO. Each filing card on this page links directly to the original SEC document.

How often does BridgeBio Pharma, Inc. file with the SEC?

BridgeBio Pharma, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BBIO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BBIO SEC Filing News — BridgeBio Pharma, Inc.

Latest SEC filings for BridgeBio Pharma, Inc. (BBIO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-13.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and…

Sector: Healthcare Industry: Biotechnology Market Cap: $13.4B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BBIO currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

BBIO Filing Activity Snapshot 2026-07-02 — 2026-10-13

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$13.16M

Cook Jennifer E. (Director) · 2026-07-13

148,589 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for BridgeBio Pharma, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 5 open-market sale, 2 tax withholding and 1 option exercise. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×2: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Open-market sale Insider Selling 2026-09-21

BBIO insider Kumar Neil (Director, Chief Executive Officer) sold 10,000 shares (~$690.8K)

Kumar Neil, listed as Director, Chief Executive Officer at BridgeBio Pharma, Inc., reported an open-market sale of 10,000 BBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	8,721	$69.01	$601.9K
`S`	Open-market sale	1,279	$69.57	$89.0K

Filing: Form 4 (Insider Transaction) Insider: Kumar Neil (Director, Chief Executive Officer) Shares: 10,000 Est. Value: $690.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-20

BBIO insider Kumar Neil (Director, Chief Executive Officer) sold 44,980 shares (~$3.73M)

Kumar Neil, listed as Director, Chief Executive Officer at BridgeBio Pharma, Inc., reported an open-market sale of 44,980 BBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,900	$81.15	$154.2K
`S`	Open-market sale	17,279	$82.21	$1.42M
`S`	Open-market sale	14,602	$82.99	$1.21M
`S`	Open-market sale	1,199	$83.77	$100.4K
`S`	Open-market sale	8,100	$83.86	$679.3K
`S`	Open-market sale	1,800	$84.69	$152.4K
`S`	Open-market sale	100	$85.65	$8.6K

Filing: Form 4 (Insider Transaction) Insider: Kumar Neil (Director, Chief Executive Officer) Shares: 44,980 Est. Value: $3.73M

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-08-18

BBIO insider Form 4 filed for equity award, exercise, or tax withholding

Trimarchi Thomas (President and CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	22,781	$79.86	$1.82M

Filing: Form 4 (Insider Transaction) Insider: Trimarchi Thomas (President and CFO) Shares: 22,781

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-08-18

BBIO insider Form 4 filed for equity award, exercise, or tax withholding

Kumar Neil (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	33,544	—	—
`M`	Option exercise	19,599	—	—
`M`	Option exercise	11,554	—	—
`M`	Option exercise	6,520	—	—
`F`	Tax withholding on vested shares	36,237	$79.86	$2.89M
`M`	Option exercise derivative · Restricted Stock Units	33,544	—	—
`M`	Option exercise derivative · Restricted Stock Units	19,599	—	—
`M`	Option exercise derivative · Restricted Stock Units	11,554	—	—
`M`	Option exercise derivative · Restricted Stock Units	6,520	—	—

Filing: Form 4 (Insider Transaction) Insider: Kumar Neil (Director, Chief Executive Officer) Shares: 107,454

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-08-18

BBIO insider Form 4 filed for equity award, exercise, or tax withholding

Apuli Maricel (Chief Accounting Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	4,714	$79.86	$376.5K

Filing: Form 4 (Insider Transaction) Insider: Apuli Maricel (Chief Accounting Officer) Shares: 4,714

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-03

BBIO insider Apuli Maricel (Chief Accounting Officer) sold 2,000 shares (~$160.1K)

Apuli Maricel, listed as Chief Accounting Officer at BridgeBio Pharma, Inc., reported an open-market sale of 2,000 BBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,000	$80.06	$160.1K

Filing: Form 4 (Insider Transaction) Insider: Apuli Maricel (Chief Accounting Officer) Shares: 2,000 Est. Value: $160.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-13

BBIO insider Ellis Andrea (Director) sold 17,167 shares (~$1.44M)

Ellis Andrea, listed as Director at BridgeBio Pharma, Inc., reported an open-market sale of 17,167 BBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	17,167	$16.75	$287.5K
`S`	Open-market sale	17,167	$84.00	$1.44M
`M`	Option exercise derivative · Stock Option (right to buy)	17,167	—	—

Filing: Form 4 (Insider Transaction) Insider: Ellis Andrea (Director) Shares: 17,167 Est. Value: $1.44M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-13

BBIO insider Cook Jennifer E. (Director) sold 148,589 shares (~$13.16M)

Cook Jennifer E., listed as Director at BridgeBio Pharma, Inc., reported an open-market sale of 148,589 BBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	19,000	$8.45	$160.6K
`M`	Option exercise	112,422	$29.00	$3.26M
`M`	Option exercise	17,167	$16.75	$287.5K
`S`	Open-market sale	36,167	$84.00	$3.04M
`S`	Open-market sale	112,422	$90.00	$10.12M
`M`	Option exercise derivative · Stock Option (Right to Buy)	19,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	112,422	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	17,167	—	—

Filing: Form 4 (Insider Transaction) Insider: Cook Jennifer E. (Director) Shares: 148,589 Est. Value: $13.16M

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. BridgeBio Pharma, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-19

BBIO Form 144 filed for proposed insider sale by KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 (30,000 shares) ~$2.49M

KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 filed a Form 144 with the SEC indicating intent to sell BBIO (BridgeBio Pharma, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 Shares: 30,000 Est. Value: $2.49M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-18

BBIO Form 144 filed for proposed insider sale by NEIL KUMAR (34,980 shares) ~$2.79M

NEIL KUMAR filed a Form 144 with the SEC indicating intent to sell BBIO (BridgeBio Pharma, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: NEIL KUMAR Shares: 34,980 Est. Value: $2.79M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-17

BBIO Form 144 filed for proposed insider sale by RANDAL SCOTT (21,501 shares) ~$1.72M

RANDAL SCOTT filed a Form 144 with the SEC indicating intent to sell BBIO (BridgeBio Pharma, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RANDAL SCOTT Shares: 21,501 Est. Value: $1.72M

View on SEC EDGAR → Open Filing Document →

Form 144 Large Proposed Insider Sale 2026-07-09

BBIO Form 144 filed for proposed insider sale by JENNIFER COOK (148,589 shares) ~$13.16M

JENNIFER COOK filed a Form 144 with the SEC indicating intent to sell BBIO (BridgeBio Pharma, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: JENNIFER COOK Shares: 148,589 Est. Value: $13.16M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-09

BBIO Form 144 filed for proposed insider sale by ANDREA ELLIS (17,167 shares) ~$1.44M

ANDREA ELLIS filed a Form 144 with the SEC indicating intent to sell BBIO (BridgeBio Pharma, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ANDREA ELLIS Shares: 17,167 Est. Value: $1.44M

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for BridgeBio Pharma, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-13